About Transmembrane protein 229A
Transmembrane protein 229A (TMEM229A) is a protein
from Homo sapiens identified by UniProt accession
B2RXF0, 380 residues long.
MolForge cross-references it against 0 known binders and
19 disease associations.
Target properties
| Protein name | Transmembrane protein 229A |
|---|
| UniProt accession | B2RXF0 |
|---|
| Gene | TMEM229A |
|---|
| Organism | Homo sapiens |
|---|
| Length | 380 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (19)
Diseases linked to this target (Open Targets).
- reaction time measurement · score 0.35
- body height · score 0.32
- non-small cell lung carcinoma · score 0.08
- Barrett's esophagus · score 0.07
- Crohn's disease · score 0.04
- lung adenocarcinoma · score 0.03
- psoriasis · score 0.02
- glioblastoma multiforme · score 0.01
- cancer · score 0.01
- esophageal adenocarcinoma · score 0.01
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-B2RXF0-F1 | alphafold | PREDICTED | 79.03 | — |
Amino-acid sequence (380 residues)
MAGSDVDSEG PARRGGAARR PGAPGGPGSE AAAGCPEPLS TAEAPAESAT LPAWMRLYFY GMHGITLDVL VSSARRFARS PDLRMLGFSS PYRCLLHSLT HFALEKVYLQ QRRCPNAFVF NFLLYPSAHV GLQTLAGQAL LLSLGGGAGV AVAPGALDLA LQYVLALYHC QVFLKRFLRL RYGRQRRRQQ QQQQQQQQQQ RRGALPVPPG ARVPTAAGAR RRRPRGPRGA GGAPSQGLPD LPRFLFFGMH GFLDEIFFTF FFNVLGQGDG TTSGHTSLWS FFMYGSCSFV VEKLYFHLHY SRGWGTWKRV PIYVIFIYVW ELSWGLGLRT CGACSWDYSH YPLNFMGLIT LMYLPGWIFL SVYQDLISNV LWRVQYVPAN
Explore Transmembrane protein 229A with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets